246 related articles for article (PubMed ID: 20829620)
1. Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy.
Kaltsas G; Makras P
Neuroendocrinology; 2010; 92 Suppl 1():60-4. PubMed ID: 20829620
[TBL] [Abstract][Full Text] [Related]
2. [Bone loss is more severe in younger Cushing's syndrome women than in older ones: comparison of bone mineral density between Cushing's syndrome and healthy women].
Jiang Y; Meng XW; Lu ZL; Xia WB; Xing XP; Li M; Wang O; Yu W; Tian JP
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1695-7. PubMed ID: 17825152
[TBL] [Abstract][Full Text] [Related]
3. [Role of cortisol hypersecretion in the pathogenesis of osteoporosis].
Chiodini I; Scillitani A
Recenti Prog Med; 2008 Jun; 99(6):309-13. PubMed ID: 18710063
[TBL] [Abstract][Full Text] [Related]
4. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
5. Skeletal morbidity in inflammatory bowel disease.
van Hogezand RA; Hamdy NA
Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623
[TBL] [Abstract][Full Text] [Related]
6. [Glucocorticoid-induced osteoporosis: recent findings].
Angeli A; Osella G; Reimondo G; Terzolo M
Ann Ital Med Int; 2000; 15(1):47-55. PubMed ID: 10842891
[TBL] [Abstract][Full Text] [Related]
7. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
Book C; Karlsson M; Akesson K; Jacobsson L
Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
[TBL] [Abstract][Full Text] [Related]
8. How should clinicians manage osteoporosis in ankylosing spondylitis?
Bessant R; Keat A
J Rheumatol; 2002 Jul; 29(7):1511-9. PubMed ID: 12136913
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
11. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome.
Tóth M; Grossman A
Clin Endocrinol (Oxf); 2013 Jul; 79(1):1-11. PubMed ID: 23452135
[TBL] [Abstract][Full Text] [Related]
13. Skeletal involvement in adult patients with endogenous hypercortisolism.
Chiodini I; Torlontano M; Carnevale V; Trischitta V; Scillitani A
J Endocrinol Invest; 2008 Mar; 31(3):267-76. PubMed ID: 18401211
[TBL] [Abstract][Full Text] [Related]
14. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
15. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
16. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
18. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
19. [Spontaneous remission of corticosteroid osteopenia after successful surgical treatment of Cushing's syndrome. A cross-sectional study].
Stĕpán J; Weiss V; Marek J; Krsek M; Masatová A; Hána V
Cas Lek Cesk; 1997 Jul; 136(15):464-7. PubMed ID: 9340192
[TBL] [Abstract][Full Text] [Related]
20. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
